Tag: Asthma Disease Market Trends

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Asthma Disease Industry By The Forecast Year 2029?

The asthma disease market has experienced robust growth over the past few years. Forecasts indicate its expansion from $24.63 billion in 2024 to $25.93 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 5.3%. This historical expansion stems from several factors, including the increasing prevalence of asthma among urban populations, elevated air pollution in industrialized areas, heightened awareness regarding asthma symptoms and diagnosis, the increased adoption of corticosteroids and bronchodilators, and improved healthcare accessibility in emerging economies.

The asthma disease market is projected to experience robust expansion over the coming years. This market is set to reach $31.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period is fueled by factors such as the increasing uptake of biologics for severe asthma, a rising demand for personalized medicine, growing investments in asthma research, the broader adoption of digital health and remote monitoring, and the expansion of telemedicine services for effective asthma management. Key trends anticipated within this period encompass advancements in biologic therapies specifically for severe asthma, the emergence of advanced inhaler technologies incorporating smart features, the creation of AI-based tools for asthma monitoring, novel approaches in personalized asthma treatment, and the development of digital health platforms designed for remote asthma management.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

What Are The Main Drivers Boosting The Asthma Disease Industry’s Expansion?

The increasing incidence of respiratory ailments is expected to drive the growth of the asthma disease market in the future. Respiratory disorders encompass a range of conditions that affect the lungs and breathing, including chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. The rising occurrence of these disorders is attributed to particulate matter and nitrogen oxides irritating and inflaming the airways, which leads to breathing difficulties and the worsening of conditions such as asthma. Respiratory diseases can cause inflammation and structural changes in the airways, either triggering or exacerbating asthma symptoms. For instance, in December 2023, the National Library of Medicine, a US-based national library, reported that by 2050, chronic obstructive pulmonary disease (COPD) cases in low- and middle-income countries are projected to more than double those in high-income countries, with sub-Saharan Africa anticipated to see a 59% increase and lead globally in COPD prevalence and cases by 2040. Therefore, the growing prevalence of respiratory disorders is stimulating the expansion of the asthma disease market.

How Is The Asthma Disease Market Segmented?

The asthma disease market covered in this report is segmented –

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy

2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma

3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent

4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration

5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users

Subsegments:

1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines

2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics

3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy

4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

What Are The Major Trends Driving The Growth Of The Asthma Disease Market?

Leading companies in the asthma disease market are concentrating on developing solutions like monoclonal antibody therapies to improve treatment effectiveness and patient outcomes. Monoclonal antibody therapy is a type of targeted treatment that employs laboratory-made proteins to mimic the immune system’s capacity to combat harmful pathogens, thereby offering more precise and effective management for chronic conditions such as asthma. For example, in June 2022, the National Institutes of Health (NIH), a US-based medical research agency, initiated the PANDA trial (preventing asthma in high-risk kids) to assess the monoclonal antibody dupilumab as a therapy for asthma in urban youth. The PANDA trial is a Phase 2, randomized, placebo-controlled study that evaluates dupilumab in approximately 240 children aged 6–17 who have poorly controlled, type 2 inflammation, high allergic asthma and reside in low-income urban areas. Participants receive subcutaneous injections every two weeks for one year alongside standard asthma care, with a 2:1 randomization to dupilumab or placebo. The trial also encompasses mechanistic studies using nasal swabs and blood samples to analyze gene expression, particularly during respiratory viral infections, with the aim of understanding the molecular pathways of asthma exacerbations and treatment response within this high-risk pediatric population.

Which Global Market Leaders Are Shaping The Future Of The Asthma Disease Sector?

Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Asthma Disease Market?

North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Asthma Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

Browse Through More Reports Similar to the Global Asthma Disease Market 2025, By The Business Research Company

Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Asthma Disease Market Be Worth By 2029?

In recent times, the market size for asthma disease has seen significant growth. It’s estimated to rise from $24.63 billion in 2024 and reach a value of $25.93 billion in 2025, representing a compound annual growth rate (CAGR) of 5.3%. The prior growth can be largely credited to the increasing instances of asthma among urban dwellers, escalating levels of air pollution in industrial areas, heightened awareness surrounding asthma symptoms and their diagnosis, the growing usage of corticosteroids and bronchodilators, as well as the widening reach of healthcare in developing countries.

The market for asthma disease is predicted to experience robust expansion in the forthcoming years, poised to reach $31.56 billion in 2029 with a compound annual growth rate (CAGR) of 5.0%. Factors such as an escalating acceptance of biologics for serious asthma, the growing demand for tailored medication, increased asthma research investments, the rise of digital health and remote monitoring, and wider reach of telemedicine services for managing asthma are attributing to the growth expected in the forecast period. Key trends during this period encompass breakthroughs in biologic treatments for severe asthma, technological upgrades in inhalers with intelligent features, the invention of AI-driven tools for asthma monitoring, inventiveness in individualized asthma therapy methods, and the evolution of digital health platforms for overseeing asthma remotely.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

Which Key Factors Are Fueling Growth In The Asthma Disease Market?

The asthma disease market is anticipated to experience growth, driven by the increasing occurrence of respiratory disorders. These disorders, which include ailments such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma, have an adverse effect on the lungs and breathing. The rise in these disorders can be attributed to the irritation and inflammation of the airways caused by particulate matter and nitrogen oxides, resulting in breathing challenges and the exacerbation of conditions like asthma. Inflammation and airway remodeling due to respiratory diseases can induce or intensify asthma symptoms. As per the National Library of Medicine, a national library in the US, it was projected in December 2023, that by 2050, COPD instances in low- and middle-income countries would be over double those in high-income countries. It was also anticipated that sub-Saharan Africa will witness a 59% increase in COPD, making it the global leader in COPD prevalence and cases by 2040. Therefore, the upsurge in respiratory disorders is fuelling the expansion of the asthma disease market.

Which Segmentation Factors Are Critical In The Asthma Disease Market Analysis?

The asthma disease market covered in this report is segmented –

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy

2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma

3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent

4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration

5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users

Subsegments:

1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines

2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics

3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy

4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

What Are The Dominant Trends Currently Seen In The Asthma Disease Market?

Leading firms in the asthma disease market are concentrating their efforts on creating monoclonal antibody therapies, with a goal of improving treatment outcomes and effectiveness. This type of targeted therapy involves the use of fabricated proteins that imitate the immune system’s defensive properties against harmful intruders, thus making the management of chronic disorders like asthma more accurate and efficient. For example, in June 2022, the National Institutes of Health (NIH), a medical research unit based in the US, initiated the PANDA (preventing asthma in high-risk children) trial to assess dupilumab, a monoclonal antibody, as a potential treatment for asthma in urban children. The PANDA trial is a stage-2, randomized, placebo-controlled study testing dupilumab on roughly 240 children, aged 6-17, suffering from poorly controlled, type 2 inflammation, severe allergy-induced asthma residing in low-income urban neighborhoods. These participants receive subcutaneous injections bi-weekly for a year, along with regular asthma care and at a 2:1 randomization ratio to dupilumab or placebo. Additionally, the trial aims to comprehend the asthma exacerbation molecular pathways and treatment response in this vulnerable pediatric group through mechanistic studies using nasal swabs and blood samples for examining gene expression, specifically during respiratory viral infections.

Which Players Are Shaping The Competitive Landscape Of The Asthma Disease Market?

Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Asthma Disease Market?

North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

Browse Through More Reports Similar to the Global Asthma Disease Market 2025, By The Business Research Company

Asthma Spacers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-spacers-global-market-report

Chronic Obstructive Pulmonary Disease Copd And Asthma Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-and-asthma-devices-global-market-report

Black Lung Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/black-lung-disease-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Asthma Disease Market Heading Into 2029?

In recent times, the market size for asthma disease has seen significant expansion. The growth is expected to continue, increasing from $24.63 billion in 2024 to $25.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.3%. This progress during the historical period is linked to various factors such as the escalating incidence of asthma among city dwellers, rising levels of air pollution in industrial areas, an increased awareness regarding the symptoms and diagnosis of asthma, a surge in the use of corticosteroids and bronchodilators, and an improvement in healthcare accessibility in emerging countries.

The market size for asthma disease is anticipated to experience robust growth in the forthcoming years, with projections indicating it will surge to $31.56 billion by 2029, marking a compound annual growth rate (CAGR) of 5.0%. This expected growth is likely due to several factors, including a higher uptake of biologics for serious asthma cases, an increase in personalized medicine demand, amplified investments in asthma-related research, bolstered usage of digital health and remote patient monitoring, and a growth in telemedicine services for the management of asthma. The future trends for the predicted period involve progression in biologic therapies for severe asthma, advanced inhaler technologies integrated with smart features, the advent of AI-enabled tools for asthma monitoring, innovative strategies for personalized asthma treatment, and the creation of digital health platforms designed for the remote supervision of asthma management.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

Which Factors Are Pushing The Asthma Disease Market Forward?

The increase in respiratory diseases is anticipated to drive the expansion of the asthma disease market. These respiratory diseases, which include chronic obstructive pulmonary disease (COPD), bronchitis, and asthma, are a group of illnesses that impact the lungs and breathing. The escalation of these disorders is mainly due to airway irritation and inflammation by particulate matter and nitrogen oxides, which results in breathing difficulties and exacerbation of conditions like asthma. Such diseases can elicit inflammation and airway remodeling, thus triggering or exacerbating asthma symptoms. As per the US-based National Library of Medicine, in December 2023, the projection for the year 2050 is that chronic obstructive pulmonary disease (COPD) cases in low- and middle-income nations will more than double those in higher-income nations, with sub-Saharan Africa anticipated to witness a 59% surge, making it the global leader in COPD prevalence and cases by 2040. Consequently, the escalating prevalence of respiratory ailments is augmenting the growth of the market for asthma disease.

Which Segment Held The Largest Share In The Asthma Disease Market In 2025?

The asthma disease market covered in this report is segmented –

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy

2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma

3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent

4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration

5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users

Subsegments:

1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines

2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics

3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy

4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

How Are Key Trends Driving Expansion In The Asthma Disease Industry?

Leading corporations in the asthma disease market are concentrating on creating solutions like monoclonal antibody therapies to boost treatment effectiveness and patients’ results. Monoclonal antibody therapy is a specialised treatment form that utilizes lab-manufactured proteins to replicate the immune system’s capacity to counter damaging pathogens, thus providing a more exact and successful management of chronic diseases such as asthma. For example, in June 2022, the US-based medical research body, the National Institutes of Health (NIH), instituted the PANDA trial (preventing asthma in high-risk kids) to assess the monoclonal antibody dupilumab as a therapy for urban youth suffering from asthma. The PANDA trial, a Phase 2, randomized, placebo-controlled study aims to test dupilumab in about 240 children ranging from ages 6-17 years with poorly controlled, type 2 inflammation, severe allergic asthma residing in low-income urban regions. Participants get subcutaneous injections bi-weekly for a year along with standard asthma care, and are randomized in a 2:1 ratio to receive dupilumab or a placebo. The trial also features mechanistic investigations utilizing nasal swabs and blood samples to study gene expression, primarily during respiratory viral infections, with a goal to comprehend the molecular pathways of asthma flare-ups and treatment responsiveness in this high-risk pediatric group.

Which Organizations Are Driving Progress In The Asthma Disease Industry?

Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Asthma Disease Industry?

North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model